BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Immune Design Corporation Raises $32 Million in Series B Financing


7/26/2010 6:38:14 AM

SEATTLE, July 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32 million in Series B financing. The round was led by ProQuest Investments and was joined by current investors: The Column Group, Versant Ventures, and Alta Partners. The Series B financing brings the total amount of equity capital raised by IDC to $50 million since its inception in 2008.

As part of the financing, ProQuest general partner, Alain Schreiber, M.D., will join IDC as its newest board member. He remarked, "I am delighted to be given the opportunity to work with the IDC team. I have been impressed by the innovative science, experienced management, and strong financial backing IDC has garnered to date. I look forward to contributing to the IDC efforts that could generate multiple products addressing medically important needs."

Steven Reed, Ph.D., IDC's co-founder and Chief Executive Officer commented, "Our strong team of investors, combined with the addition of ProQuest and the appointment of Dr. Schreiber to our board, further validates the exciting potential of our technology platforms and our vision to develop and commercialize breakthrough vaccine products worldwide. The closing of the Series B provides resources for accelerating IDC's lead candidates through clinical studies and further expanding development of new vaccines and therapeutics."

IDC is advancing an innovative vaccine pipeline utilizing its two proprietary technologies which include GLA, a novel, synthetic, toll-like receptor 4 (TLR-4) agonist, which is a clinical stage adjuvant being developed as a component in multiple internal and partnered vaccine programs; and DC-NILV, a novel delivery vector engineered to target human dendritic cells and express target antigens and immunomodulatory elements to elicit functional and broad based immunity, which is initially being applied in cancer indications of significant unmet need.

About Immune Design Corp.

Immune Design Corp. is a privately held biotechnology company based in Seattle, WA. IDC brings together some of the world's leaders in the field of molecular immunology to develop vaccines for the prevention and treatment of infectious and malignant disease. The company employs advanced and leading edge methods to precisely control the activation and context of antigen presentation by dendritic cells in order to shape the desired adaptive immune response. For more information, go to www.immunedesign.com.

Media Relations:

Immune Design Corp. Cassie Ostrander (206) 826-7901 cassie.ostrander@immunedesign.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES